Dr. Muzzaffar Qazilbash, MD
Claim this profileClinical Trials Muzzaffar Qazilbash, MD is currently running
More about Muzzaffar Qazilbash, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Muzzaffar Qazilbash, MD has experience with
- Isatuximab
- Lenalidomide
Breakdown of trials Muzzaffar Qazilbash, MD has run
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Muzzaffar Qazilbash, MD specialize in?
Muzzaffar Qazilbash, MD focuses on Multiple Myeloma and other conditions. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Muzzaffar Qazilbash, MD currently recruiting for clinical trials?
Yes, Muzzaffar Qazilbash, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Muzzaffar Qazilbash, MD has studied deeply?
Yes, Muzzaffar Qazilbash, MD has studied treatments such as Isatuximab, Lenalidomide.
What is the best way to schedule an appointment with Muzzaffar Qazilbash, MD?
Apply for one of the trials that Muzzaffar Qazilbash, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.